Related Experiment Video
Updated: Jan 20, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
Gilteritinib in an Isolated CNS Recurrence of FLT3-ITD Positive AML
Lina Susana Silva-Bermudez1, Alexander Streuer2, Foteini Christodoulou2
1Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim Heidelberg University Mannheim Germany.
None:
Central nervous system (CNS) involvement in adult acute myeloid leukemia (AML) is uncommon and more frequently observed at relapse than at initial presentation. Typically, CNS relapse coincides with systemic disease, evidenced by detectable blasts in the bone marrow (BM) and/or peripheral blood. We describe a rare case of an 82-year-old patient with a history of AML, diagnosed three and a half years earlier, who developed an isolated CNS relapse while receiving palliative chemotherapy-without concurrent BM involvement or molecular evidence of systemic progression. Cerebrospinal fluid (CSF) analysis revealed blast cells harboring an FLT3 internal tandem duplication (FLT3-ITD). Targeted therapy with an FLT3 tyrosine kinase inhibitor (TKI) achieved complete remission, with clearance of FLT3-ITD from the CSF.
Related Concept Videos
04:36Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
06:29Dissection of Larval CNS in Drosophila Melanogaster
07:32Assessment of Vascular Regeneration in the CNS Using the Mouse Retina
08:53Recurrent Escherichia coli Urinary Tract Infection Triggered by Gardnerella vaginalis Bladder Exposure in Mice
CNS Depressants: Alcohol and Nicotine

